Moderna: Vaccine Approval (Finally!) Provides A Reason To Be Cheerful

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?Moderna (NASDAQ: MRNA ) shares are down over 35% year-to-date, over 80% on a one-year basis, and since reaching their pandemic era high of over $450 per share, they are down 94%.The group is for both novice and expe ...